True or false? Alzheimer’s disease is type 3 diabetes: Evidences from bench to bedside

• Published in: Ageing research reviews 2024-08, Vol.99, p.102383, Article 102383
• Main Authors: Peng, Yong, Yao, Shun-yu, Chen, Quan, Jin, Hong, Du, Miao-qiao, Xue, Ya-hui, Liu, Shu
• Format: Article
• Language: English
• Subjects: Alzheimer's Disease; Brain insulin resistance in type 2 diabetes; Clinical trials; Insulin; Tau protein; Type 3 diabetes; β-amyloid protein
• ISSN: 1568-1637; 1872-9649; 1872-9649
• DOI: 10.1016/j.arr.2024.102383

Globally, Alzheimer's disease (AD) is the most widespread chronic neurodegenerative disorder, leading to cognitive impairment, such as aphasia and agnosia, as well as mental symptoms, like behavioral abnormalities, that place a heavy psychological and financial burden on the families of the afflicted. Unfortunately, no particular medications exist to treat AD, as the current treatments only impede its progression.The link between AD and type 2 diabetes (T2D) has been increasingly revealed by research; the danger of developing both AD and T2D rises exponentially with age, with T2D being especially prone to AD. This has propelled researchers to investigate the mechanism(s) underlying this connection. A critical review of the relationship between insulin resistance, Aβ, oxidative stress, mitochondrial hypothesis, abnormal phosphorylation of Tau protein, inflammatory response, high blood glucose levels, neurotransmitters and signaling pathways, vascular issues in AD and diabetes, and the similarities between the two diseases, is presented in this review. Grasping the essential mechanisms behind this detrimental interaction may offer chances to devise successful therapeutic strategies.